Additionally, phase II research (NCT04619420) is being conducted that will continue until 2025, evaluating the safety and effectiveness of, and tolerance to JNJ-63733657 in individuals with early-stage AD who have a positive tau PET scan. This evidence concerns the gene MAPT and Alzheimer disease.